Delcath Systems (OTCMKTS: DCTHD) and ReWalk Robotics (NASDAQ:RWLK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Institutional and Insider Ownership

3.2% of ReWalk Robotics shares are owned by institutional investors. 0.0% of Delcath Systems shares are owned by insiders. Comparatively, 13.7% of ReWalk Robotics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Delcath Systems and ReWalk Robotics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Delcath Systems -1,278.64% -3,960.73% -165.16%
ReWalk Robotics -346.14% -568.25% -90.30%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Delcath Systems and ReWalk Robotics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems 0 0 0 0 N/A
ReWalk Robotics 1 0 3 0 2.50

ReWalk Robotics has a consensus target price of $3.38, suggesting a potential upside of 206.82%. Given ReWalk Robotics’ higher possible upside, analysts clearly believe ReWalk Robotics is more favorable than Delcath Systems.

Volatility & Risk

Delcath Systems has a beta of -0.59, suggesting that its stock price is 159% less volatile than the S&P 500. Comparatively, ReWalk Robotics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Earnings & Valuation

This table compares Delcath Systems and ReWalk Robotics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Delcath Systems $1.99 million 0.08 -$17.97 million ($1,377.67) 0.00
ReWalk Robotics $5.87 million 5.42 -$32.50 million ($1.59) -0.69

Delcath Systems has higher earnings, but lower revenue than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Summary

ReWalk Robotics beats Delcath Systems on 11 of the 12 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

About ReWalk Robotics

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.

Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.